LLY Stock Chart & Fundamental Analysis

Interactive Chart

About Eli Lilly and Company

Name

Eli Lilly and Company

CEO

David A. Ricks

Website

www.lilly.com

Industry

Healthcare

Year Founded

1876

Employees

50,000

Eli Lilly and Company researches, develops, and commercializes human medicines, operating as a large pharmaceutical company listed on the NYSE as LLY. Its portfolio spans diabetes, oncology, immunology, neuroscience, and other specialty therapies, and it recorded $65.2 billion of revenue in FY2025.

Analyst Ratings

Consensus Recommendation

Buy6

Hold2

Sell0

Fundamentals & Financials

Revenue (TTM)

$79.6B

Net Income (TTM)

$26.7B

EPS (TTM)

$29.85

ROA (TTM)

18.77%

Current Ratio

1.35

Dividend Yield

0.14%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Item	Q2 FY2026	Q1 FY2026	Q4 FY2025
Revenue	$22,974M	$19,799M	$19,292M
Cost of Sales	$3,268M	$3,577M	$2,883.7M
Gross Profit	$19,706M	$16,222M	$16,408.3M
Operating Income	$8,978M	$8,850M	$8,775.3M
Net Income	$7,095M	$7,396M	$6,636M
EPS	$7.95	$8.27	$7.41

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings Calendar

Technical Indicators

Eli Lilly and Company's Technical Indicators Summary

LLY displays a strong bullish technical profile driven by broad-based moving average support and positive momentum. The stock trades well above its short-, medium- and long-term averages, MACD is positive and momentum readings are constructive, while OBV confirms buying interest. ADX is subdued, indicating the trend is not extreme, and ATR shows moderate volatility for the price level. The classic pivot sits below the market, adding a supportive reference. Technical takeaway: multiple timeframe moving averages, momentum and volume are aligned to a strong buy outlook.

Buy

6 signals

Neutral

2 signals

Sell

0 signals

Overall: Bullish75% Bullish signals

Indicator	Value	Signal	Explanation
RSI (14)	57.85	Neutral	RSI (57.85) is neutral.
Stochastic %K (14, 3, 3)	66.59	Neutral	Stochastic (66.59) is neutral.
CCI (20)	80.62	—	CCI (80.62) is neutral.
WPR (14)	-10.97	—	Williams %R (-10.97) > -20, indicating overbought.
Momentum (10)	110.05	—	Momentum (110.05) is positive.
MFI	47.86	—	MFI (47.86) is neutral.
MACD Level (12, 26)	11.41	Buy	Confirmed uptrend: MACD (11.41) is positive and above its signal line (9.75).
Bollinger Bands	$1120.52 - $1252.16	—	Price is within the bands.
ATR (14)	$40.46 (3.30%)	—	Moderate Volatility (3.30%).
ADX (14)	18.87	—	Weak or consolidating trend (ADX < 25). ADX(18.87), +DI(28.91), -DI(20.44)
OBV	91,427,528	—	Bullish volume pressure: OBV is above its 20-day SMA. OBV(91,427,528), 20D-SMA-OBV(90,118,848)
Classic Pivot Point	$1181.73	—	Price ($1225.73) has broken above resistance R1 ($1199.95) — bullish breakout potential.
Fibonacci Pivot Point	$1181.73	—	Price ($1225.73) has broken above resistance R1 ($1195.10) — bullish breakout potential.
Simple Moving Averages	$1047.10 - $1201.28(5 indicators)	—	SMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key SMA averages.
Exponential Moving Averages	$1036.76 - $1197.70(5 indicators)	Buy	EMA group: 5/5 bullish, 0 bearish, 0 neutral. Price above key EMA averages.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

By the end of the session, LLY held much of its 3.68% gain versus yesterday. End-of-day, the peer group was modestly in the green at 1.59%, providing a small boost to sentiment. LLY rises as BMO reiterates Buy with a $1,400 target.

Trading Volume

Below 10d avg (2.8M)

1.8M

vs S&P 500 Today

Strong Outperformance

+4.28%

52-Week Position

Near highs

96%

Updated: August 18, 2026 at 20:08 UTC